124 related articles for article (PubMed ID: 11061343)
1. Inhibitory effect of liposomal MDP-Lys on lung metastasis of transplantable osteosarcoma in hamster.
Nitta Y; Sugita T; Ikuta Y; Murakami T
Oncol Res; 2000; 12(1):25-31. PubMed ID: 11061343
[TBL] [Abstract][Full Text] [Related]
2. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
3. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
Phillips NC; Tsao MS
Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
[TBL] [Abstract][Full Text] [Related]
5. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
6. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
8. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
Mori K; Ando K; Heymann D
Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
[TBL] [Abstract][Full Text] [Related]
10. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
[TBL] [Abstract][Full Text] [Related]
11. Mutagenicity studies of muroctasin.
Shimada H; Hattori C; Sato T
Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
[TBL] [Abstract][Full Text] [Related]
12. Local tolerance of muroctasin injection in rabbits.
Nakashima K; Jindo T; Nomura M
Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
[TBL] [Abstract][Full Text] [Related]
13. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
14. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
Nagao S; Sato K; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination.
Mehta RT; Lopez-Berestein G; Hopfer RL; Mehta K; White RA; Juliano RL
Antimicrob Agents Chemother; 1985 Oct; 28(4):511-3. PubMed ID: 4073873
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.
Lopez-Berestein G; Milas L; Hunter N; Mehta K; Hersh EM; Kurahara CG; Vandupas M; Eppstein DA
Clin Exp Metastasis; 1984; 2(2):127-37. PubMed ID: 6543694
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell binding and induction of endothelial cell tumoricidal activity in vitro by muramyl dipeptide is enhanced by liposomal encapsulation.
Phillips NC; Stewart-Phillips J; Wang P
J Immunother Emphasis Tumor Immunol; 1994 Apr; 15(3):185-93. PubMed ID: 8032541
[TBL] [Abstract][Full Text] [Related]
18. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
19. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
Ishihara C; Yamamoto K; Hamada N; Azuma I
Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
[TBL] [Abstract][Full Text] [Related]
20. Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.
Phillips NC; Tsao MS
Cancer Immunol Immunother; 1991; 33(2):85-90. PubMed ID: 2036662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]